A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
TENAX THERAPEUTICS, INC.
TENX
$406M
Mkt Cap
$14.53
-0.75%
TENAX THERAPEUTICS, INC. (TENX) has a 5-year average return on invested capital (ROIC) of 37.8%. This indicates strong capital allocation and a potential competitive advantage.
TENAX THERAPEUTICS, INC. (TENX) has a market capitalization of $406M. It is classified as a small-cap stock.
TENAX THERAPEUTICS, INC. (TENX) does not currently pay a regular dividend.
TENAX THERAPEUTICS, INC. (TENX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
TENAX THERAPEUTICS, INC. (TENX) generated $-36 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
TENAX THERAPEUTICS, INC. (TENX) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
TENAX THERAPEUTICS, INC. (TENX) reported earnings per share (EPS) of $-1.88 in its most recent fiscal year.
Tenax Therapeutics is a clinical-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. We employ a clinician-focused drug development approach, led by key opinion leaders and heart failure experts and informed by their clinical insights to precisely target disease pathophysiology. We are currently actively conducting the LEVEL clinical trial to evaluate levosimendan as our prioritized product candidate and have deprioritized a Phase 3 clinical trial of imatinib, two drugs supported by promising evidence that they may significantly improve the lives of patients with pulmonary hypertension. Importantly, both levosimendan and imatinib have already been approved in other indications and prescribed around the world for more than 20 years, and we believe their mechanisms of action are uniquely suitable to target and treat pulmonary hypertension.
| Metric | TTM | FY2025 | FY2024 | FY2021 | FY2020 | FY2016 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | - | - | 0 |
| Net Income | -53M | -53M | -18M | -32M | -9.9M | 44M |
| EPS | $-1.88 | $-1.88 | $-1.72 | $-51.53 | $-1.90 | $312.40 |
| Free Cash Flow | -36M | -36M | -15M | -11M | -9.3M | -16M |
| ROIC | -42.7% | -55.5% | -20.2% | -431.5% | 113.5% | 113.3% |
| Gross Margin | - | 0.0% | 0.0% | - | - | - |
| Debt/Equity | 0.00 | 0.00 | - | 0.13 | 0.07 | 0.00 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | - | - | - |
| Operating Income | -56M | -56M | -19M | -33M | 9.9M | -53M |
| Operating Margin | 0.0% | 0.0% | 0.0% | - | - | - |
| ROE | -54.2% | -55.6% | - | -765.1% | -234.6% | 113.3% |
| Shares Outstanding | 28M | 28M | 10M | 1M | 5M | 0M |
| Metric | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | 0 | N/A | N/A | 0 | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% | N/A |
| R&D | 2.7M | 2.5M | 2.5M | 3.0M | 6.7M | 13M | 4.6M | 25M | 13M | 33M | 33M |
| SG&A | 7.7M | 6.1M | 3.7M | 14M | 7.2M | 6.2M | 5.3M | 7.6M | 6.8M | 24M | 24M |
| EBIT | 11M | -8.2M | -5.2M | -17M | -15M | -53M | 9.9M | -33M | -19M | -56M | -56M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% | 0.0% |
| Net Income | 10M | 16M | 10M | 25M | 14M | 44M | -9.9M | -32M | -18M | -53M | -53M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% | 0.0% |
| Non-Recurring | 302K | 30K | 233K | -3K | 112K | 33M | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||
| ROIC | N/M | N/M | N/M | 59.0% | 19.7% | 113.3% | 113.5% | N/M | -20.2% | -55.5% | -42.7% |
| ROE | N/A | N/A | N/A | 62.5% | 19.7% | 113.3% | -234.6% | -765.1% | N/A | -55.6% | -54.2% |
| ROA | 357.5% | 444.8% | 283.3% | 52.5% | 16.9% | 91.2% | -148.9% | -505.0% | -32.5% | -52.4% | -50.5% |
| Cash Flow | |||||||||||
| Op. Cash Flow | 8.4M | 8.3M | 4.9M | 9.3M | 9.7M | -16M | -9.3M | -11M | -15M | -36M | -36M |
| Free Cash Flow | 8.2M | 8.3M | 4.9M | 9.3M | 9.7M | -16M | -9.3M | -11M | -15M | -36M | -36M |
| Owner Earnings | 8.0M | 7.9M | 4.6M | 8.5M | 9.5M | -16M | -9.5M | -12M | -16M | -55M | -55M |
| CapEx | 241K | 18K | 17K | 10K | 4K | 3K | 3K | 5K | 0 | 0 | 0 |
| Maint. CapEx | 311K | 207K | 149K | 150K | 148K | 19K | 4K | 4K | 0 | 0 | 0 |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1K | N/A | N/A | 0 |
| D&A | 311K | 207K | 149K | 150K | 148K | 19K | 4K | 4K | 0 | 0 | 0 |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 59K | 128K | 185K | 651K | 117K | 1K | 253K | 802K | 1.1M | 19M | 19M |
| Debt Repayment | 0 | 8.0M | 8.0M | 0 | 0 | 0 | 0 | 245K | 0 | 0 | 0 |
| Balance Sheet | |||||||||||
| Net Debt | 3.5M | 3.1M | 4.2M | -58M | -20M | -13M | -6.4M | -5.0M | -94M | -98M | -98M |
| Cash & Equiv. | 952K | 1.9M | 784K | 58M | 3.7M | 10.0M | 6.3M | 5.6M | 95M | 98M | 98M |
| Long-Term Debt | 0 | 4.9M | 4.9M | 0 | N/A | 0 | 124K | 245K | 501K | 0 | N/A |
| Debt/Equity | -1.20 | -14.34 | -2.79 | 0.00 | 0.00 | 0.00 | 0.07 | 0.13 | N/A | 0.00 | 0.00 |
| Interest Coverage | 61.6 | -1.1 | -1.2 | -7.5 | -301.9 | N/A | 6065.1 | -34487.1 | -847.6 | N/A | N/A |
| Equity | -3.7M | -346K | -1.8M | 83M | 60M | 17M | 4.6M | 4.2M | N/A | 97M | 97M |
| Total Assets | 2.9M | 4.1M | 3.2M | 93M | 73M | 23M | 6.9M | 6.0M | 97M | 104M | 104M |
| Total Liabilities | 6.6M | 4.5M | 5.0M | 11M | 13M | 6.2M | 2.2M | 1.7M | N/A | 7.2M | 7.2M |
| Intangibles | 700K | 873K | 925K | 23M | 22M | 0 | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -92M | -108M | -117M | -137M | -161M | -205M | -246M | -278M | -315M | -367M | -367M |
| Working Capital | -551K | -496K | -67K | 56M | 16M | 7.4M | 4.7M | 4.1M | 92M | 97M | 97M |
| Current Assets | 1.6M | 2.6M | 1.8M | 59M | 21M | 14M | 6.8M | 5.7M | 97M | 104M | 104M |
| Current Liabilities | 2.2M | 3.1M | 1.9M | 2.6M | 4.6M | 6.2M | 2.1M | 1.6M | 4.7M | 7.2M | 7.2M |
| Per Share Data | |||||||||||
| EPS | 120.59 | -3,798.90 | 1,335.80 | -81.30 | 5.01 | 312.40 | -1.90 | -51.53 | -1.72 | -1.88 | -1.88 |
| Owner EPS | 92.71 | N/A | 590.68 | N/A | 3.37 | -113.02 | -1.84 | -18.51 | -1.55 | -1.97 | -1.97 |
| Book Value | -42.99 | N/A | -228.95 | N/A | 21.49 | 121.91 | 0.89 | 6.74 | N/A | 3.47 | 3.47 |
| Cash Flow/Share | 96.99 | N/A | 633.69 | N/A | 3.47 | -112.88 | -1.79 | -17.23 | -1.44 | -1.28 | -1.88 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 | 0.00 |
| Shares Out. | 0.1M | N/A | 0.0M | N/A | 2.8M | 0.1M | 5.2M | 0.6M | 10.3M | 27.9M | 27.9M |
| Valuation | |||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -7.7 |
| P/FCF | N/A | N/A | 245.3 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | 4.9 | 2.5 | N/A | N/A | N/A | N/A | 0.5 | 0.5 | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | 1.3 | 1.5 | 3.2 | 2.4 | 5.1 | N/A | N/A | 4.2 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | 17.1% | 39.1% | 3.6% | 8.8% | 10.4% | -29.2% | -83.6% | -50.3% | N/A | N/A | -8.8% |
| Market Cap | 48M | 21M | 136M | 105M | 94M | 54M | 11M | 22M | 0 | 0 | 406M |
| Avg. Price | 1,341,543.31 | 955,351.71 | 160,093.08 | 150,124.88 | 109,501.46 | 75,150.55 | 1,789.96 | 2,905.52 | 0.00 | 0.00 | 14.53 |
| Year-End Price | 985,600.00 | 435,200.00 | 154,880.00 | 119,360.00 | 106,560.00 | 61,760.00 | 1,712.00 | 1,680.00 | 0.00 | 0.00 | 14.53 |
TENAX THERAPEUTICS, INC. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 37.8%.
TENAX THERAPEUTICS, INC. (TENX) has a return on equity (ROE) of -55.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 10 years of financial data for TENAX THERAPEUTICS, INC. (TENX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
TENAX THERAPEUTICS, INC. (TENX) has a book value per share of $3.47, based on its most recent annual SEC filing.